Serum 25-hydroxyvitamin D levels and health outcomes of hospitalization owing to COVID-19: a retrospective cross-sectional study

Irina Metonidze,Nestan Bostoganashvili,Tamar Goderidze,David Tananashvili
DOI: https://doi.org/10.1177/03000605241271770
2024-08-30
Journal of International Medical Research
Abstract:Journal of International Medical Research, Volume 52, Issue 8, August 2024. ObjectiveWe investigated the role of serum 25(OH)D (25-hydroxyvitamin D) in COVID-related health outcomes.MethodsWe conducted a retrospective cross-sectional study using data of the National Center of Disease Control and Public Health, Georgia. We extracted patient data including length of hospital stay, transfer to the intensive care unit, requirement for oxygen therapy, treatment with glucocorticoids, and symptoms. After obtaining written informed consent, 384 individuals were enrolled. We divided participants into three groups according to 25(OH)D levels: group 1 = 25(OH)D 20 ng/mL (n = 160).ResultsThe odds ratio (OR) for hospitalization in group 1 versus group 2 was 8.7 (95% confidence interval [CI] 3.6–21.3) and 5.6 for group 1 versus 3 (95% CI 2.7–11.9). Regarding oxygen therapy, OR = 28.41 for group 1 versus 2 (95% CI 3.7–220.5) and OR = 5.2 for group 1 versus 3 (95% CI 1.9–14.1). Regarding treatment with glucocorticoids, OR = 3.7 for group 1 versus 2 (95% CI 1.1–12.5) and OR = 8.4 for group 1 versus 3 (95% CI 1.8–40.7).ConclusionCOVID-19-related morbidity was associated with decreased serum 25(OH)D levels. Future studies should investigate the potential role of vitamin D sufficiency in preventing SARS-CoV-2 infection and mortality.
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?